BREAKING NEWS
ROURKELA - WORKSHOP ORGANIZED ON SENSITIZATION –CUM-ORIENTATION ON PLASTIC WASTE MANAGEMENT
NATIONAL - FORMER PM AB VAJPAYEE’S HEALTH CRITICAL, SAID AIIMS BULLETIN
KEONJHAR - 11 GOOD SAMARITANS REWARDED FOR HELPING ROAD MISHAP VICTIMS
INDEPENDENCE DAY CELEBRATED ACROSS ODISHA
CONTACT Us FOR ANUBHABA MONTHLY ODIA NEWS MAGAZINE
72ND INDEPENDENCE DAY CELEBRATED AT TALCHER KANIHA
Launching of newer drug for treatment of Diabetes at Berhampur

Launching of newer drug for treatment of Diabetes at Berhampur Featured

Report;Bureau,Odishabarta 

Berhampur: Seven crore Indian people are suffering from Diabetes. The existing set of oral antidiabetic drugs help to control sugars in the initial phase. As the duration of diabetes progresses, the beta cells of pancreas which produce insulin gradually degenerate making it difficult for the existing drugs to reduce sugars in advanced stage. To bring down the rising blood sugars in these cases, there are several newer drugs being scientifically developed. An academic meeting was held yesterday to launch one such newer drug GLYXAMBI for the first time in Berhampur. Dr Sunil Kumar Kota, Consultant Endocrinologist from Diabetes & Endocare Clinic, Berhampur was the chief speaker for the event, chaired by senior physician Prof Dr P C Sahu, Ex Head of the Dept, Gen Medicine, MKCG Medical College. Dr Kota highlighted the usage pattern, efiicacy and safety profile this of drug to the audience. 

 GLYXAMBI is a fixed dose combination of 2 molecules ie EMPAGLIFLOZIN, a SGLT2 receptor inhibitor and LINAGLIPTIN, a DPP4 inhibitor. SGLT2 receptors are located in the kidney tubules, help in entry of glucose from urine into blood. Empagliflozin blocks these SGLT2 receptors and prevents absorption of glucose into blood leading to excretion of around 80 grams glucose through urine per day. It reduces blood glucose even in long standing diabetics, where other drugs tend to fail. It has additional advantages of reduction of body weight, blood pressure and cholesterol, avoidance of hypoglycaemia. Recent scientific study EMPAREG has demonstrated significant reduction of cardiovascular complications and mortality in patients taking Empagliflozin. Linaglitptin, a DPP4 enzyme inhibitor increases blood level of an incretin hormone, namely GLP 1. This GLP 1 acts on pancreatic beta cells to produce insulin and prevents their degeneration in advanced diabetes. The combination drug ie GLYXAMBI improves kidney health and reduces of insulin requirement for diabetes treatment. Additionally there is greater reduction of body weight and blood pressure with far better sugar control than the individual drugs used alone. 

Total of around 60 doctors from MKCG Medical college and private practitioners of Berhampur attended the session. Renowned doctors like Prof Sarat Ch Mohanty, prof Saroj Panda, Dr Pramod Patnaik also graced the occasion. Dr Sunil Kota concluded the session by question and answer on GLYXAMBI, with the audience.

Read 499 times Last modified on Monday, 04 June 2018 09:01
Rate this item
(1 Vote)

About Author

Visitors Counter

130634448
Today
Yesterday
This Week
Last Week
This Month
Last Month
All days
1790
5568
46184
85556
89499
72566
130634448

Your IP: 54.198.126.110
2018-08-16 10:33
X

Right Click

No right click